Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases, 2006

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2006 Oct 14

PMID 17038465

Citations 20

Authors

D E Furst

F C Breedveld

J R Kalden

J S Smolen

G R Burmester

P Emery

E C Keystone

M H Schiff

P L C M Van Riel

M E Weinblatt

M H Weisman

Affiliations

Soon will be listed here.

Citing Articles

A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy.

Elsanhoury A, Tschope C, Van Linthout S J Cardiovasc Transl Res. 2020; 14(1):75-87.

PMID: 32440911 PMC: 7892499. DOI: 10.1007/s12265-020-10025-4.

Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.

Kolarz B, Majdan M, Darmochwal-Kolarz D, Dryglewska M Med Sci Monit. 2014; 20:1227-31.

PMID: 25027437 PMC: 4109570. DOI: 10.12659/MSM.890270.

Steroids Decrease Prevalence of Positive Tuberculin Skin Test in Rheumatoid Arthritis: Implications on Anti-TNF Therapies.

Agarwal S, Das S, Agarwal G, Srivastava R Interdiscip Perspect Infect Dis. 2014; 2014:430134.

PMID: 24707285 PMC: 3953622. DOI: 10.1155/2014/430134.

Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis.

Rosa J, Sabelli M, Soriano E Med Devices (Auckl). 2012; 3:25-31.

PMID: 22915918 PMC: 3417862. DOI: 10.2147/mder.s7504.

ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.

Girlanda S, Mantegani P, Baldissera E, Aiello P, Ratti M, Sabbadini M Clin Rheumatol. 2010; 29(10):1135-41.

PMID: 20645117 DOI: 10.1007/s10067-010-1532-1.

References

Cusack C, Buckley C . Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006; 154(4):726-9. DOI: 10.1111/j.1365-2133.2005.07067.x. View

Stone J, Holbrook J, Marriott M, Tibbs A, Sejismundo L, Min Y . Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006; 54(5):1608-18. DOI: 10.1002/art.21869. View

Andonopoulos A, Meimaris N, Daoussis D, Bounas A, Giannopoulos G . Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis. 2003; 62(11):1116. PMC: 1754369. DOI: 10.1136/ard.62.11.1116. View

Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G . Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med. 2005; 143(12):918-20. DOI: 10.7326/0003-4819-143-12-200512200-00019. View

Bang L, Keating G . Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004; 18(2):121-39. DOI: 10.2165/00063030-200418020-00005. View

Cortis E, De Benedetti F, Insalaco A, Cioschi S, Muratori F, DUrbano L . Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. J Pediatr. 2004; 145(6):851-5. DOI: 10.1016/j.jpeds.2004.08.001. View

Clegg D, Reda D, Mejias E, Cannon G, Weisman M, Taylor T . Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996; 39(12):2013-20. DOI: 10.1002/art.1780391210. View

Bathon J, Martin R, Fleischmann R, Tesser J, Schiff M, Keystone E . A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343(22):1586-93. DOI: 10.1056/NEJM200011303432201. View

Fleischmann R, Iqbal I, Stern R . Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2004; 3(5):391-403. DOI: 10.1517/14740338.3.5.391. View

10.

. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005; 352(4):351-61. DOI: 10.1056/NEJMoa041884. View

11.

van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P . Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63(5):508-16. PMC: 1755008. DOI: 10.1136/ard.2003.013052. View

12.

Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I . Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2002; 44(12):2933-5. DOI: 10.1002/1529-0131(200112)44:12<2933::aid-art482>3.0.co;2-y. View

13.

Hull K, Drewe E, Aksentijevich I, Singh H, Wong K, McDermott E . The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore). 2002; 81(5):349-68. DOI: 10.1097/00005792-200209000-00002. View

14.

Shekelle P, Woolf S, Eccles M, Grimshaw J . Clinical guidelines: developing guidelines. BMJ. 1999; 318(7183):593-6. PMC: 1115034. DOI: 10.1136/bmj.318.7183.593. View

15.

Antin J, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee S . Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood. 2002; 100(10):3479-82. DOI: 10.1182/blood-2002-03-0985. View

16.

Bresnihan B . The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2001; 30(5 Suppl 2):17-20. DOI: 10.1053/sarh.2001.23701. View

17.

Simon A, Bodar E, van der Hilst J, van der Meer J, Fiselier T, Cuppen M . Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med. 2004; 117(3):208-10. DOI: 10.1016/j.amjmed.2004.02.039. View

18.

Carter J . Treatment of relapsing polychondritis with a TNF antagonist. J Rheumatol. 2005; 32(7):1413. View

19.

Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P . Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002; 46(12):3317-26. DOI: 10.1002/art.10699. View

20.

Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G . Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2004; 64(2):229-34. PMC: 1755337. DOI: 10.1136/ard.2004.025130. View